106 related articles for article (PubMed ID: 32833943)
1. Impact of a Prior Nonpancreatic Malignancy on Survival Outcomes of Patients With Stage IV Pancreatic Neuroendocrine Tumor: A Population-Based and Propensity Score Matching Study.
Li G; Tian ML; Bing YT; Yuan CH; Xiu DR
Pancreas; 2020 Sep; 49(8):1090-1098. PubMed ID: 32833943
[TBL] [Abstract][Full Text] [Related]
2. Does Prior Cancer Have an Influence on the Survival Outcomes of Patients with Localized Pancreatic Neuroendocrine Tumors?
Wang L; Li G; Bing YT; Tian ML; Wang HY; Yuan CH; Xiu DR
Chin Med Sci J; 2021 Dec; 36(4):284-294. PubMed ID: 34986965
[TBL] [Abstract][Full Text] [Related]
3. Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort.
Al-Husseini MJ; Saad AM; Turk T; Tabash MA; Abdel-Rahman O
J Gastrointest Cancer; 2019 Dec; 50(4):794-800. PubMed ID: 30105523
[TBL] [Abstract][Full Text] [Related]
4. The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas.
Wen J; Chen J; Liu D; Xu X; Fan M; Zhang Z
Neuroendocrinology; 2020; 110(5):364-376. PubMed ID: 31357196
[TBL] [Abstract][Full Text] [Related]
5. Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors.
Kauffmann RM; Wang L; Phillips S; Idrees K; Merchant NB; Parikh AA
Ann Surg Oncol; 2014 Oct; 21(11):3422-8. PubMed ID: 25059786
[TBL] [Abstract][Full Text] [Related]
6. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).
Kim SJ; Kim JW; Oh DY; Han SW; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
Am J Clin Oncol; 2012 Dec; 35(6):549-56. PubMed ID: 21659833
[TBL] [Abstract][Full Text] [Related]
7. Impact of prior malignancy on outcomes of stage IV esophageal carcinoma: SEER based study.
Saad AM; Al-Husseini MJ; Elgebaly A; Aboshady OA; Salahia S; Abdel-Rahman O
Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):417-423. PubMed ID: 29316808
[TBL] [Abstract][Full Text] [Related]
8. Outcomes in patients with pancreatic cancer as a secondary malignancy: a retrospective single-institution study.
Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Ogata Y
Langenbecks Arch Surg; 2019 Dec; 404(8):975-983. PubMed ID: 31768632
[TBL] [Abstract][Full Text] [Related]
9. Outcomes after primary tumor resection of metastatic pancreatic neuroendocrine tumors: An analysis of the National Cancer Database.
Kaslow SR; Hani L; Cohen SM; Wolfgang CL; Sacks GD; Berman RS; Lee AY; Correa-Gallego C
J Surg Oncol; 2023 Aug; 128(2):262-270. PubMed ID: 37042430
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of Hepatocellular Carcinoma Among Cancer Survivors with Other Types of Primary Tumors.
Bian X; He X; Yang L; Wu W; Li L
Dig Dis Sci; 2020 Jul; 65(7):2140-2147. PubMed ID: 31673904
[TBL] [Abstract][Full Text] [Related]
11. Impact of prior cancer history on survival in brain malignancy: A propensity score-adjusted, population-based study.
Ebad Ur Rehman M; Faraz F; Cheema HA; Ashruf OS; Raheel H; Naqvi SZA; Jabeen N; Abid A; Mumtaz Malik H; Iftikhar A; Ibrahim A; Swed S
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1984. PubMed ID: 38389401
[TBL] [Abstract][Full Text] [Related]
12. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
13. Impact of prior cancer history on survival of patients with gastric cancer.
Wen L; Yu K; Lu H; Zhong G
Eur J Surg Oncol; 2021 Sep; 47(9):2286-2294. PubMed ID: 33632589
[TBL] [Abstract][Full Text] [Related]
14. Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria.
Martin JA; Warner RR; Wisnivesky JP; Kim MK
Eur J Cancer; 2017 May; 76():197-204. PubMed ID: 28334622
[TBL] [Abstract][Full Text] [Related]
15. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.
Rindi G; Falconi M; Klersy C; Albarello L; Boninsegna L; Buchler MW; Capella C; Caplin M; Couvelard A; Doglioni C; Delle Fave G; Fischer L; Fusai G; de Herder WW; Jann H; Komminoth P; de Krijger RR; La Rosa S; Luong TV; Pape U; Perren A; Ruszniewski P; Scarpa A; Schmitt A; Solcia E; Wiedenmann B
J Natl Cancer Inst; 2012 May; 104(10):764-77. PubMed ID: 22525418
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic features, incidence, and survival trends of gynecologic neuroendocrine tumors: a SEER database analysis.
Gibbs J; Mei S; Economos K; Lee YC; Kanis MJ
Am J Obstet Gynecol; 2019 Jul; 221(1):53.e1-53.e6. PubMed ID: 30849352
[TBL] [Abstract][Full Text] [Related]
17. Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis.
Hüttner FJ; Schneider L; Tarantino I; Warschkow R; Schmied BM; Hackert T; Diener MK; Büchler MW; Ulrich A
Langenbecks Arch Surg; 2015 Aug; 400(6):715-23. PubMed ID: 26198970
[TBL] [Abstract][Full Text] [Related]
18. Effect of prior cancer on survival outcomes for patients with advanced prostate cancer.
Wu Y; Chen X; Qian D; Wang W; Zhang Y; Hu J; Zhu J; Wu Q; Cao T
BMC Urol; 2021 Feb; 21(1):26. PubMed ID: 33596896
[TBL] [Abstract][Full Text] [Related]
19. Does a history of malignancy impact the survival of a subsequent endometrial adenocarcinoma? Should clinical trials eligibility criteria be revisited?
Mohamed HH; Ibrahim Sokkar M; Afifi AM; Saad AM; Albarouki S; Al-Husseini MJ
J Obstet Gynaecol; 2020 Feb; 40(2):233-239. PubMed ID: 31352852
[TBL] [Abstract][Full Text] [Related]
20. The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age.
Partelli S; Muffatti F; Rancoita PMV; Andreasi V; Balzano G; Crippa S; Doglioni C; Rubini C; Zamboni G; Falconi M
Dig Liver Dis; 2019 May; 51(5):735-740. PubMed ID: 30723019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
